|
|
 Previous Article | Table of Contents | Next Article 
Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma
Randy D. Gascoyne,
Sheryle A. Adomat,
Stanislaw Krajewski,
Maryla Krajewska,
Douglas E. Horsman,
Anthony W. Tolcher,
Susan E. O'Reilly,
Paul Hoskins,
Andrew J. Coldman,
John C. Reed, and
Joseph M. Connors
From the Departments of Pathology, Medical Oncology, and Biostatistics, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; and The Burnham Institute, Cancer Research Center, La Jolla, CA.
The prognostic significance of Bcl-2 protein expression and bcl-2 gene rearrangement in diffuse large cell lymphomas (DLCL) is controversial. Bcl-2 protein expression prevents apoptosis and may have an important role in clinical drug resistance. The presence of a bcl-2 gene rearrangement in de novo DLCL suggests a possible follicle center cell origin and perhaps a distinct clinical behavior more akin to low-grade non-Hodgkin's lymphoma (NHL). The purpose of this study was to determine the impact of Bcl-2 protein expression and bcl-2 gene rearrangement (mbr and mcr) on survival of a cohort of patients with DLCL who were uniformly evaluated and treated with effective chemotherapy. Patients included the original MACOP-B cohort (n = 121) and the initial 18 patients treated with the VACOP-B regimen (total = 139). All patients had advanced-stage disease, were 16 to 70 years old, and corresponded to Working Formulation categories F, G, or H. No patients had prior treatment, discordant lymphoma, or human immunodeficiency virus seropositivity. Paraffin sections from diagnostic biopsies were analyzed for bcl-2 gene rearrangement including mbr and mcr breakpoints by polymerase chain reaction and Bcl-2 protein expression by immunohistochemistry. With a median follow-up of 81 months, overall (OS), disease-free (DFS), and relapse-free survival (RFS) were measured to determine the prognostic significance of these parameters. Analyzable DNA was present in 118 of 139 (85%) cases, with 14 demonstrating a bcl-2 rearrangement (11 mbr, 3 mcr). All 14 of these bcl-2 gene rearrangement-positive cases were found in the 102 patients with a B-cell immunophenotype, but the presence of this rearrangement had no significant influence on survival. Bcl-2 protein expression was interpretable in 116 of 139 (83%) cases, with immunopositivity detected in 54 of 116 (47%). Using a cut-off of greater than 10% Bcl-2 immunopositive tumor cells for analysis, positive Bcl-2 protein expression was seen in 28 of 116 (24%) patients and the presence of this expression correlated with decreased 8-year OS (34% v 60%, P < .01), DFS (32% v 66%, P < .001), and RFS (25% v 59%, P < .001). Bcl-2 protein expression remained significant in multivariate analysis that included the clinical international prognostic index factors and immunophenotype (P < .02). In conclusion, although bcl-2 gene rearrangement status could not be shown to have an impact on outcome, Bcl-2 protein expression is a strong significant predictor of OS, DFS, and RFS in DLCLs.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 244-251
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Dierlamm, E. M. Murga Penas, S. Bentink, S. Wessendorf, H. Berger, M. Hummel, W. Klapper, D. Lenze, A. Rosenwald, E. Haralambieva, et al.
Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma
Haematologica,
May 1, 2008;
93(5):
688 - 696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Reed
Bcl-2-family proteins and hematologic malignancies: history and future prospects
Blood,
April 1, 2008;
111(7):
3322 - 3330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Morel, P. Gaulard, C. Gisselbrecht, C. Ferme, G. Salles, H. Tilly, J. Briere, M. C. Copin, P. Lederlin, O. Hermine, et al.
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2
Ann. Onc.,
March 1, 2008;
19(3):
560 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. LeBrun, T. Baetz, C. Foster, P. Farmer, R. Sidhu, H. Guo, K. Harrison, R. Somogyi, L. D. Greller, and H. Feilotter
Predicting Outcome in Follicular Lymphoma by Using Interactive Gene Pairs
Clin. Cancer Res.,
January 15, 2008;
14(2):
478 - 487.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. G. M. Cillessen, J. C. Reed, K. Welsh, C. Pinilla, R. Houghten, E. Hooijberg, J. Deurhof, K. C. M. Castricum, P. Kortman, C. J. Hess, et al.
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells
Blood,
January 1, 2008;
111(1):
369 - 375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Le Gouill, P. Talmant, C. Touzeau, A. Moreau, R. Garand, N. Juge-Morineau, F. Gaillard, T. Gastinne, N. Milpied, P. Moreau, et al.
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement
Haematologica,
October 1, 2007;
92(10):
1335 - 1342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Prakash and S. H Swerdlow
Nodal aggressive B-cell lymphomas: a diagnostic approach
J. Clin. Pathol.,
October 1, 2007;
60(10):
1076 - 1085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al.
Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma
Haematologica,
June 1, 2007;
92(6):
778 - 783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, and S. Leppa
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy
Blood,
June 1, 2007;
109(11):
4930 - 4935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
Ann. Onc.,
May 1, 2007;
18(5):
931 - 939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. de Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, A. Lee, B. Sander, C. Thorns, E. Campo, T. Molina, et al.
Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications--A Study From the Lunenburg Lymphoma Biomarker Consortium
J. Clin. Oncol.,
March 1, 2007;
25(7):
805 - 812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. van Imhoff, E.-J. G. Boerma, B. van der Holt, E. Schuuring, L. F. Verdonck, H. C. Kluin-Nelemans, and P. M. Kluin
Prognostic Impact of Germinal Center-Associated Proteins and Chromosomal Breakpoints in Poor-Risk Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 1, 2006;
24(25):
4135 - 4142.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Wallace, D. Shen, G. F. Reed, M. Miyanaga, M. Mochizuki, H. N. Sen, S. S. Dahr, R. R. Buggage, R. B. Nussenblatt, and C.-C. Chan
Detection of the bcl-2 t(14;18) Translocation and Proto-Oncogene Expression in Primary Intraocular Lymphoma.
Invest. Ophthalmol. Vis. Sci.,
July 1, 2006;
47(7):
2750 - 2756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kaderali, T. Zander, U. Faigle, J. Wolf, J. L. Schultze, and R. Schrader
CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data
Bioinformatics,
June 15, 2006;
22(12):
1495 - 1502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, E. A. Weller, S. J. Horning, M. Krajewska, D. Variakojis, T. M. Habermann, R. I. Fisher, P. J. Kurtin, W. R. Macon, M. Chhanabhai, et al.
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Blood,
June 1, 2006;
107(11):
4207 - 4213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tzankov, A. Gschwendtner, F. Augustin, M. Fiegl, E. C. Obermann, S. Dirnhofer, and P. Went
Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
Clin. Cancer Res.,
April 1, 2006;
12(7):
2125 - 2132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Oncologist,
April 1, 2006;
11(4):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos and D. Morgensztern
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
995 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Iqbal, V. T. Neppalli, G. Wright, B. J. Dave, D. E. Horsman, A. Rosenwald, J. Lynch, C. P. Hans, D. D. Weisenburger, T. C. Greiner, et al.
BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
961 - 968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Camilleri-Broet, E. Criniere, P. Broet, V. Delwail, K. Mokhtari, A. Moreau, M. Kujas, M. Raphael, W. Iraqi, C. Sautes-Fridman, et al.
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases
Blood,
January 1, 2006;
107(1):
190 - 196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Tome, D. B. F. Johnson, L. M. Rimsza, R. A. Roberts, T. M. Grogan, T. P. Miller, L. W. Oberley, and M. M. Briehl
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis
Blood,
November 15, 2005;
106(10):
3594 - 3601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. De Paepe, R. Achten, G. Verhoef, I. Wlodarska, M. Stul, V. Vanhentenrijk, M. Praet, and C. De Wolf-Peeters
Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas
J. Clin. Oncol.,
October 1, 2005;
23(28):
7060 - 7068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hachem and R. B. Gartenhaus
Oncogenes as molecular targets in lymphoma
Blood,
September 15, 2005;
106(6):
1911 - 1923.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A K H Shia, G-G Gan, S Jairaman, and S-C Peh
High frequency of germinal centre derivation in diffuse large B cell lymphoma from Asian patients
J. Clin. Pathol.,
September 1, 2005;
58(9):
962 - 967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hoffmann, M. Tiemann, C. Schrader, D. Janssen, E. Wolf, M. Vierbuchen, R. Parwaresch, K. Ernestus, A. Plettenberg, A. Stoehr, et al.
AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping
Blood,
September 1, 2005;
106(5):
1762 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson and M. A. Shipp
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
Blood,
August 15, 2005;
106(4):
1164 - 1174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lopez-Guillermo, L. Colomo, M. Jimenez, F. Bosch, N. Villamor, L. Arenillas, A. Muntanola, S. Montoto, E. Gine, D. Colomer, et al.
Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin
J. Clin. Oncol.,
April 20, 2005;
23(12):
2797 - 2804.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bea, L. Colomo, A. Lopez-Guillermo, I. Salaverria, X. Puig, M. Pinyol, S. Rives, E. Montserrat, and E. Campo
Clinicopathologic Significance and Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell Lymphomas
J. Clin. Oncol.,
September 1, 2004;
22(17):
3498 - 3506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. W. Tolcher, J. Kuhn, G. Schwartz, A. Patnaik, L. A. Hammond, I. Thompson, H. Fingert, D. Bushnell, S. Malik, J. Kreisberg, et al.
A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res.,
August 1, 2004;
10(15):
5048 - 5057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos, D. K. Czerwinski, A. A. Alizadeh, M. A. Wechser, R. Tibshirani, D. Botstein, and R. Levy
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes
N. Engl. J. Med.,
April 29, 2004;
350(18):
1828 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-I. Saez, A.-J. Saez, M.-J. Artiga, A. Perez-Rosado, F.-I. Camacho, A. Diez, J.-F. Garcia, M. Fraga, R. Bosch, S.-M. Rodriguez-Pinilla, et al.
Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma
Am. J. Pathol.,
February 1, 2004;
164(2):
613 - 622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Hans, D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie, G. Ott, H. K. Muller-Hermelink, E. Campo, R. M. Braziel, E. S. Jaffe, et al.
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
Blood,
January 1, 2004;
103(1):
275 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. de Jong, A. M. Glas, L. Boerrigter, M.-C. Hermus, O. Dalesio, E. Willemse, P. M. Nederlof, and M. J. Kersten
Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features
Blood,
July 1, 2003;
102(1):
324 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Barrans, P. A. S. Evans, S. J. M. O'Connor, S. J. Kendall, R. G. Owen, A. P. Haynes, G. J. Morgan, and A. S. Jack
The t(14;18) Is Associated with Germinal Center-derived Diffuse Large B-Cell Lymphoma and Is a Strong Predictor of Outcome
Clin. Cancer Res.,
June 1, 2003;
9(6):
2133 - 2139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mounier, J. Briere, C. Gisselbrecht, J.-F. Emile, P. Lederlin, C. Sebban, F. Berger, A. Bosly, P. Morel, H. Tilly, et al.
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
Blood,
June 1, 2003;
101(11):
4279 - 4284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Terol, M. Tormo, J. A. Martinez-Climent, I. Marugan, I. Benet, A. Ferrandez, A. Teruel, R. Ferrer, and J. Garcia-Conde
Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome
Ann. Onc.,
March 1, 2003;
14(3):
467 - 474.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Braaten, R. A. Betensky, L. de Leval, Y. Okada, F. H. Hochberg, D. N. Louis, N. L. Harris, and T. T. Batchelor
BCL-6 Expression Predicts Improved Survival in Patients with Primary Central Nervous System Lymphoma
Clin. Cancer Res.,
March 1, 2003;
9(3):
1063 - 1069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Mi, S. D. Thomas, X. Xu, L. K. Casson, D. M. Miller, and P. J. Bates
Apoptosis in Leukemia Cells Is Accompanied by Alterations in the Levels and Localization of Nucleolin
J. Biol. Chem.,
February 28, 2003;
278(10):
8572 - 8579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos, A. A. Alizadeh, R. Rajapaksa, R. Tibshirani, and R. Levy
HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma
Blood,
January 15, 2003;
101(2):
433 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
